News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Defence Therapeutics Inc.'s AccuTOX published in the prestigious Journal of Translational Medicine along with preclinical data on AccuTOX as an anti-cancer molecule. Study highlights AccuTOX's superior therapeutic properties and versatility for different cancer treatments -
-
-
COMMUNIQUÉ DE PRESSE
Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale
Theranexus et BBDF confirment les résultats positifs à 18 mois de l'étude de phase 1/2 sur les neurofilaments, biomarqueur de la mort neuronale, concernant le médicament Batten-1 dans la maladie de Batten (CLN3) -
COMMUNIQUÉ DE PRESSE
Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential -
COMMUNIQUÉ DE PRESSE
Inside Information / News release on accounts, results
